晚期肾癌免疫检查点治疗新进展
作者:
作者单位:

作者简介:

通讯作者:

中图分类号:

基金项目:

国家自然科学基金(81270685);南京市科技局项目(201605001)


Advances in immune checkpoint inhibitors for advanced renal cell carcinoma
Author:
Affiliation:

Fund Project:

  • 摘要
  • |
  • 图/表
  • |
  • 访问统计
  • |
  • 参考文献
  • |
  • 相似文献
  • |
  • 引证文献
  • |
  • 资源附件
  • |
  • 文章评论
    摘要:

    肾癌是我国泌尿系统最常见的恶性肿瘤之一。目前早期肾癌仍主张手术治疗,但晚期肾癌患者则以药物治疗为主。随着血管内皮生长因子(vascular endothelial growth factor,VEGF)抑制剂和mTOR抑制剂等靶向药物接连获批应用于晚期肾癌患者,极大地改善了患者预后,但临床上靶向药物的耐药性问题也日益凸显。近年来免疫治疗快速发展,尤其是程序性死亡受体(programmed cell death-1,PD-1)及其配体(programmed cell death-ligand 1,PD-L1)抑制剂与细胞毒T淋巴细胞相关性抗原-4(cytotoxic T lymphocyte-associated antigen-4,CTLA-4)抑制剂等免疫检查点抑制剂在相关临床试验中的良好表现,进一步改善了患者预后。本文就免疫检查点抑制剂治疗晚期肾癌的最新研究进展作一综述。

    Abstract:

    Renal cell carcinoma(RCC) is one of most common urinary malignant tumors in China. Surgery is the first selection for the early stage RCC,whereas drug therapy is preferred for the advanced RCC. As VEGF and mTOR inhibitors are approved for the treatment of advanced RCC,the clinical application of targeted drugs improves patients’ prognosis. However,the resistance to VEGF and mTOR targeted therapies is becoming increasingly prominent. In recent decades,immunotherapy,especially programmed cell death-1(PD-1)/programmed cell death-ligand 1(PD-L1) inhibitors and cytotoxic T lymphocyte-associated antigen-4(CTLA-4) inhibitors,has been rapidly developing. These novel checkpoint inhibitors perform well in many clinical trials and improve treatment outcome. This article summarizes the latest data in the development of checkpoint inhibitors for patients with advanced kidney cancer.

    参考文献
    相似文献
    引证文献
引用本文

田 野,王尚乾,苗陈岿,朱俊栋,秦 超,王增军.晚期肾癌免疫检查点治疗新进展[J].南京医科大学学报(自然科学版),2019,(1):153-157

复制
分享
文章指标
  • 点击次数:
  • 下载次数:
  • HTML阅读次数:
  • 引用次数:
历史
  • 收稿日期:2017-08-01
  • 最后修改日期:
  • 录用日期:
  • 在线发布日期: 2019-02-21
  • 出版日期:
通知关闭
郑重声明